Evidence map›Paper›PMID 24005862›Full record

ArticleInternational journal of molecular sciences2013

Comparative analysis of human mesenchymal stem cells from bone marrow, adipose tissue, and umbilical cord blood as sources of cell therapy.

Hye Jin Jin, Yun Kyung Bae, Miyeon Kim, Soon-Jae Kwon, Hong Bae Jeon, Soo Jin Choi, Seong Who Kim, Yoon Sun Yang, Wonil Oh, Jong Wook Chang

2 registry-linked trialsOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 351 papers, 11 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
351citing papers in PubMed, 11 pooled it
17.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02307435 early_phase1unknown statusnot on this mapstarted 2014, after this paper: background citation

Potency of Allogenic Bone Marrow, Umbilical Cord, Adipose Mesenchymal Stem Cell for Non Union Fracture and Long Bone Defect, Directly and Cryopreserved

TypeinterventionalSponsorIndonesia UniversityRan2014 to 2017Enrolled9ConditionsNon Union Fracture, Metaphyseal Fibrous DefectArmsMSC
NCT06882811 early_phase1recruitingnot on this mapstarted 2025, after this paper: background citation

Clinical Study on Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Sepsis

TypeinterventionalSponsorDaping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityRan2025 to 2027Enrolled180ConditionsSepsisArmsCD83-positive MSC, regulatory MSC, control solution
3 · Its place in the literature

Who cites it

351 citing papers in PubMed, 11 syntheses or guidelines pooled it, 659 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Trial
  13. Trial
  14. Review
  15. Review
  16. Review
  17. Review
  18. Article
  19. Article
  20. [Research advances in mesenchymal stem cell therapy for graft-versus-host disease].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2026
    Review

291 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Hye Jin JinBiomedical Research Institute, MEDIPOST Co., Ltd., Seoul 137-874, Korea. genny77@medi-post.co.kr
Yun Kyung Bae
Miyeon Kim
Soon-Jae Kwon
Hong Bae Jeon
Soo Jin Choi
Seong Who Kim
Yoon Sun Yang
Wonil Oh
Jong Wook Chang
Medipost (South Korea) · KRUlsan College · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Various source-derived mesenchymal stem cells (MSCs) have been considered for cell therapeutics in incurable diseases. To characterize MSCs from different sources, we compared human bone marrow (BM), adipose tissue (AT), and umbilical cord blood-derived MSCs (UCB-MSCs) for surface antigen expression, differentiation ability, proliferation capacity, clonality, tolerance for aging, and paracrine activity. Although MSCs from different tissues have similar levels of surface antigen expression, immunosuppressive activity, and differentiation ability, UCB-MSCs had the highest rate of cell proliferation and clonality, and significantly lower expression of p53, p21, and p16, well known markers of senescence. Since paracrine action is the main action of MSCs, we examined the anti-inflammatory activity of each MSC under lipopolysaccharide (LPS)-induced inflammation. Co-culture of UCB-MSCs with LPS-treated rat alveolar macrophage, reduced expression of inflammatory cytokines including interleukin-1α (IL-1α), IL-6, and IL-8 via angiopoietin-1 (Ang-1). Using recombinant Ang-1 as potential soluble paracrine factor or its small interference RNA (siRNA), we found that Ang-1 secretion was responsible for this beneficial effect in part by preventing inflammation. Our results demonstrate that primitive UCB-MSCs have biological advantages in comparison to adult sources, making UCB-MSCs a useful model for clinical applications of cell therapy.

Indexed as

Adipose TissueAdolescentAdultAngiopoietin-1Blotting, WesternBone Marrow CellsCell- and Tissue-Based TherapyChildFetal BloodHumansImmunophenotypingInterleukin-1alphaInterleukin-6Interleukin-8Mesenchymal Stem CellsYoung AdultAngiopoietin-1Interleukin-1alphaInterleukin-6Interleukin-8

Identifiers

PMID24005862
PMCPMC3794764
OpenAlexW2156509094

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.